432 related articles for article (PubMed ID: 15966213)
1. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
Lai IR; Hu RH; Chang KJ
Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
[TBL] [Abstract][Full Text] [Related]
2. Giant GIST of the small intestine in a young man.
Atmatzidis S; Chatzimavroudis G; Ananiadis A; Kapoulas S; Atmatzidis K
J Gastrointest Surg; 2013 Aug; 17(8):1536-7. PubMed ID: 23797887
[TBL] [Abstract][Full Text] [Related]
3. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK
Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565
[No Abstract] [Full Text] [Related]
4. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
5. A treatment using STI571 for jejunal gastrointestinal stromal tumor (GIST) accompanied with liver metastasis and peritoneal dissemination.
Okamoto K; Muguruma N; Aoki R; Sato Y; Nakamoto J; Imoto Y; Okamura S; Ito S; Okitsu H; Sano T
Intern Med; 2004 Dec; 43(12):1151-6. PubMed ID: 15645649
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
7. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
9. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
11. [A case of gastrointestinal stromal tumor of the jejunum successfully treated by preoperative induction chemotherapy with imatinib mesylate administered through jejunostomy and subsequent surgical resection].
Kimura H; Ohtsuka T; Toma H; Ueda J; Mizuuchi Y; Yamamoto H; Takahata S; Oda Y; Ueki T; Tanaka M
Gan To Kagaku Ryoho; 2014 Mar; 41(3):391-4. PubMed ID: 24743291
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
13. [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
Yamanaka H; Mizushima T; Mikata S; Ito T; Nonaka K; Ide H; Michiura T; Kainuma S; Iwase K
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2125-8. PubMed ID: 16352942
[TBL] [Abstract][Full Text] [Related]
14. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E
Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005
[TBL] [Abstract][Full Text] [Related]
15. Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.
Kobayashi M; Okamoto K; Nakatani H; Okabayashi T; Namikawa T; Ichikawa K; Kitagawa H; Araki K
Surg Today; 2006; 36(8):727-32. PubMed ID: 16865518
[TBL] [Abstract][Full Text] [Related]
16. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
17. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
19. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
[TBL] [Abstract][Full Text] [Related]
20. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
